Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 88« First...34567...102030...Last »

Protagonist Therapeutics Discontinues Phase IIb Ulcerative Colitis Study

Protagonist Therapeutics Inc. discontinued a Phase IIb study for the experimental ulcerative colitis treatment PTG-100 following a review from an Independent Data Monitoring Committee (DMC).

Read More »

Pfizer’s Chantix fails study in adolescent smokers

Pfizer Inc. said the company’s study to test safety and effectiveness of its anti-smoking treatment Chantix in adolescent smokers failed to meet the main goal.

Read More »

Phase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS

Novartis announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis were published in the peer-reviewed journal The Lancet.

Read More »

Array Touts Phase III Results for Melanoma Therapy

Shares of Array BioPharma Inc. climbed after the company released detailed results for its late-stage combination treatment for metastatic melanoma.

Read More »

AbbVie not seeking faster approval for cancer drug

AbbVie Inc. said the drugmaker would not seek accelerated approval for the company’s experimental lung cancer treatment based on the results from a mid-stage study.

Read More »

Tecentriq notches third cancer cocktail trial win

Roche’s immunotherapy Tecentriq racked up a third trial win in combination with other cancer drugs, a boost for the Swiss drugmaker.

Read More »

Eylea Shows Promising Data for Diabetic Retinopathy

Regeneron Pharmaceuticals announced positive top-line data from the Phase III PANORAMA study of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.

Read More »

Heron Therapeutics Soars on Positive Phase III Results

Heron Therapeutics said the company’s late-stage anesthetic used to treat bunionectomy and hernia repair hit all primary and key secondary endpoints in two Phase III trials that cut down on the requirement of opioid drugs to treat pain.

Read More »

Americans are drinking a daily cup of coffee at the highest level in six years: survey

At-home consumption and gourmet beverages have Americans drinking a daily cup of coffee at the highest level since 2012.

Read More »

Smoking tied to higher risk of hearing loss

Smokers may be more likely to develop hearing loss than nonsmokers, and the risk increases with each additional cigarette people smoke on a typical day, a Japanese study suggests.

Read More »

Auris Medical Fails Again in Phase III Trial

Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.

Read More »

AbbVie’s Elagolix Dazzles in Phase III Trial

AbbVie and Neurocrine Biosciences announced that the Phase III ELARIS UF-II clinical trial of elagolix for uterine fibroids met its primary endpoint.

Read More »

Newer gout drug poses risk to heart patients

Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded.

Read More »

Improved Pressure-ulcer Outcomes with Wearable Technology

In the past few years, personal fitness trackers have become all the rage. It’s fun to see your daily activity level, sleep quality and heart rate. But, does knowing this data lead to any positive changes?

Read More »

Realm Therapeutics Conjunctivitis Drug Fails Phase II Trial

Realm Therapeutics Inc.’s PR013 failed to show efficacy in its Phase II trial for allergic conjunctivitis.

Read More »

Anthera’s lead drug fails study, shares slump

Anthera Pharmaceuticals Inc. is evaluating all strategic options after the company’s lead drug failed in a late-stage trial, sending shares down 80 percent in premarket trading.

Read More »

AstraZeneca lung cancer trial results pushed back

AstraZeneca expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half.

Read More »

MyoKardia Reports Positive Results in Heart Study

Shares of MyoKardia climbed after the company revealed positive results from a mid-stage clinical trial for obstructive hypertrophic cardiomyopathy.

Read More »

Sanofi, Evotec team up for research plarform

Sanofi and Evotec started exclusive talks over accelerating research into the treatment of infectious diseases and will form a new open innovation platform in this area, led by Evotec.

Read More »

Eisai, Merck Enter Strategic Oncology Collaboration

Eisai and Merck agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor.

Read More »

Page 5 of 88« First...34567...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review


Ad Right Bottom

Main Navigation